Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergio Valente

Showing results (11-20 of 155) with videos related to

Pageof 16
Sort By:
Clinical Epigenetics|June 3, 2017
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacyRoberta Mazzone, Clemens Zwergel, Antonello Mai, et al.
Frontiers in Chemistry|July 7, 2020
The Innovative Potential of Statins in Cancer: New Targets for New TherapiesElisabetta Di Bello, Clemens Zwergel, Antonello Mai, et al.
Current Pharmaceutical Design|September 16, 2009
Histone deacetylase inhibitors and neurodegenerative disorders: holding the promiseAntonello Mai, Dante Rotili, Sergio Valente, et al.
Journal of Medicinal Chemistry|August 5, 2021
Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED BindersStefano Tomassi, Annalisa Romanelli, Clemens Zwergel, et al.
Current Opinion in Chemical Biology|April 16, 2019
Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancerGiulia Stazi, Rossella Fioravanti, Antonello Mai, et al.
Chemmedchem|May 10, 2024
Heterocycles-Containing HDAC Inhibitors Active in Cancer: An Overview of the Last Fifteen YearsAlessia Raucci, Carola Castiello, Antonello Mai, et al.
Journal of Chemical Information and Modeling|May 23, 2006
3-D QSAR studies on histone deacetylase inhibitors. A GOLPE/GRID approach on different series of compoundsRino Ragno, Silvia Simeoni, Sergio Valente, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2010
Synthesis and biological evaluation of novel coumarin-based inhibitors of Cdc25 phosphatasesSergio Valente, Emilie Bana, Elodie Viry, et al.
Journal of Medicinal Chemistry|January 24, 2023
METTL3 from Target Validation to the First Small-Molecule Inhibitors: A Medicinal Chemistry JourneyFrancesco Fiorentino, Martina Menna, Dante Rotili, et al.
Current Opinion in Structural Biology|August 5, 2023
Histone deacetylase 10: A polyamine deacetylase from the crystal structure to the first inhibitorsChiara Lambona, Clemens Zwergel, Rossella Fioravanti, et al.
Pageof 16

Showing results (11-20 of 155) with videos related to

Sort By:
Pageof 16
Clinical Epigenetics|June 3, 2017
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacyRoberta Mazzone, Clemens Zwergel, Antonello Mai, et al.
Frontiers in Chemistry|July 7, 2020
The Innovative Potential of Statins in Cancer: New Targets for New TherapiesElisabetta Di Bello, Clemens Zwergel, Antonello Mai, et al.
Current Pharmaceutical Design|September 16, 2009
Histone deacetylase inhibitors and neurodegenerative disorders: holding the promiseAntonello Mai, Dante Rotili, Sergio Valente, et al.
Journal of Medicinal Chemistry|August 5, 2021
Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED BindersStefano Tomassi, Annalisa Romanelli, Clemens Zwergel, et al.
Current Opinion in Chemical Biology|April 16, 2019
Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancerGiulia Stazi, Rossella Fioravanti, Antonello Mai, et al.
Chemmedchem|May 10, 2024
Heterocycles-Containing HDAC Inhibitors Active in Cancer: An Overview of the Last Fifteen YearsAlessia Raucci, Carola Castiello, Antonello Mai, et al.
Journal of Chemical Information and Modeling|May 23, 2006
3-D QSAR studies on histone deacetylase inhibitors. A GOLPE/GRID approach on different series of compoundsRino Ragno, Silvia Simeoni, Sergio Valente, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2010
Synthesis and biological evaluation of novel coumarin-based inhibitors of Cdc25 phosphatasesSergio Valente, Emilie Bana, Elodie Viry, et al.
Journal of Medicinal Chemistry|January 24, 2023
METTL3 from Target Validation to the First Small-Molecule Inhibitors: A Medicinal Chemistry JourneyFrancesco Fiorentino, Martina Menna, Dante Rotili, et al.
Current Opinion in Structural Biology|August 5, 2023
Histone deacetylase 10: A polyamine deacetylase from the crystal structure to the first inhibitorsChiara Lambona, Clemens Zwergel, Rossella Fioravanti, et al.
Pageof 16